c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.
about
Oxidative stress responses and NRF2 in human leukaemiaRedefining ALL classification: toward detecting high-risk ALL and implementing precision medicineCXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance.The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemiaInhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiationThe miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1.The molecular mechanics of mixed lineage leukemia.Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemiaSCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cellsCBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responsesHigh-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells.Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.Dual transcriptome sequencing reveals resistance of TLR4 ligand-activated bone marrow-derived macrophages to inflammation mediated by the BET inhibitor JQ1.Activated Notch counteracts Ikaros tumor suppression in mouse and human T-cell acute lymphoblastic leukemia.The TCA cycle transferase DLST is important for MYC-mediated leukemogenesis.JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine effortsNew Approaches to Target T-ALL.Epigenetics in T-cell acute lymphoblastic leukemia.Genomics in acute lymphoblastic leukaemia: insights and treatment implications.Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.Emerging roles for the FBXW7 ubiquitin ligase in leukemia and beyond.Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.Microenvironmental cues for T-cell acute lymphoblastic leukemia development.Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders.Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.Genetic Basis of Acute Lymphoblastic Leukemia.A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers.The Varied Roles of Notch in Cancer.CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphomaThe BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALLRUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia.Targeting oncoproteins for degradation by small molecules in myeloid leukemia.Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.
P2860
Q26864239-8F73725A-9339-44A5-A9FB-A95D1A154715Q26864460-18FD15D2-A29D-4043-A897-800B1F70377AQ27324358-41503D95-644B-401D-A441-E5C8E8ABC0A9Q28075211-F392992C-6BCF-4334-9B07-8E4A9A7ECE01Q28542016-F0D131EB-3903-4EBF-B5DD-A7B22211A999Q33591618-0AF775F3-64D6-4228-9C67-BE68F2BA0921Q34516051-849A4C76-9E88-424E-A7DD-D03ED9A76EC1Q34645214-ADC825CA-35CE-4EBB-A1A7-B829FCAB3CFFQ34732289-CEE9346E-6BB3-45C3-BA53-C2C1055D6CD6Q36008355-BF431C79-652A-40BD-B935-DDC17CE80C41Q36178314-9274DEC6-65E0-490E-A327-F236E10A437FQ36214162-195C6294-3ABA-412F-BE45-D6316270A89DQ36298080-C3E944C8-3A5D-41F2-A2FD-6F93EE3C5CA3Q36837426-B48CE2C7-6244-461E-BFCA-6AAEA1BB18C2Q36957835-21409009-6DE9-444D-9BAD-F2D65C8671B9Q37687075-0DDDC4AD-5592-4567-B3BC-FD0F20CFB13BQ37708933-816D3EF2-C094-4E91-8B0F-9D69B488B44BQ37733990-85433FE8-F0CA-4F37-94B9-602E9B784467Q38234993-5BF56CC9-31AF-4EF2-920F-18226B73F16FQ38289023-3FDADCE0-4F11-4505-8093-E427CA70AB3AQ38381463-089EA28F-02FF-4C13-9493-E0D284C5B806Q38409231-5CD5CC34-569E-4605-83C8-E0F941B251D0Q38542092-83808576-1634-4EBA-A513-F78FE4F64893Q38596749-AC102832-AB9B-4FAB-B53E-5A5300D225B2Q38722012-496E6ECA-DEA4-4A31-9FBF-03F1A7AA78DCQ38779981-79F31D4C-D2B7-41F0-8E2A-D8AEF2726840Q38810904-DE5F5F7C-E17B-4010-AEF4-1B4CAF216B53Q38823047-701A85B2-1B57-4B66-8DDE-CAC112D788D8Q38866094-8866F193-CB46-4DCB-8495-70A1D655C820Q39024306-0558CDD7-9AAD-4AEF-9179-B9EF16A4A151Q39180500-5927AD8B-9364-44AB-9601-3BD53B30E7AAQ39207675-4F227852-E4B1-4056-AE96-A10B55C52831Q40411894-DA9EB984-3777-47C2-9CC0-7F6F71665AAFQ42334357-0CBDCC9B-7375-404C-A0D2-7DF4694E10B8Q42372332-634E3317-3BC5-41A7-81D0-1D5C0275F358Q42701804-409C9B90-6915-443E-9CA4-A356B93DF136Q42705204-2E94E1E2-85FF-4F21-89E4-0DBC6CC76AB1Q45065002-7A5765CF-FB7F-49BC-84A2-72C7CD735EB1Q47337952-62EDE13B-5051-4BDC-80D0-4F42EC08C7FDQ47368952-53036DAA-C66D-4A43-9411-69B10D797781
P2860
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
c-Myc inhibition prevents leuk ...... failure pediatric T-ALL cells.
@en
c-Myc inhibition prevents leuk ...... failure pediatric T-ALL cells.
@nl
type
label
c-Myc inhibition prevents leuk ...... failure pediatric T-ALL cells.
@en
c-Myc inhibition prevents leuk ...... failure pediatric T-ALL cells.
@nl
prefLabel
c-Myc inhibition prevents leuk ...... failure pediatric T-ALL cells.
@en
c-Myc inhibition prevents leuk ...... failure pediatric T-ALL cells.
@nl
P2093
P2860
P1433
P1476
c-Myc inhibition prevents leuk ...... failure pediatric T-ALL cells.
@en
P2093
A Thomas Look
Dale L Greiner
James E Bradner
Jessica Tesell
Justine E Roderick
Leonard D Shultz
Lewis B Silverman
Marian H Harris
Michael A Brehm
P2860
P304
P356
10.1182/BLOOD-2013-08-522698
P407
P577
2014-01-06T00:00:00Z